DT Investment Partners LLC Has $11 Million Position in Johnson & Johnson (NYSE:JNJ)

DT Investment Partners LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 68,086 shares of the company’s stock after buying an additional 2,315 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of DT Investment Partners LLC’s portfolio, making the stock its 20th largest holding. DT Investment Partners LLC’s holdings in Johnson & Johnson were worth $10,996,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of JNJ. Newton One Investments LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $32,000. Robbins Farley LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $33,000. Lion Street Advisors LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $36,000. Finally, Alpha Paradigm Partners LLC acquired a new stake in Johnson & Johnson in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 67.14% of the company’s stock.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $172.00 target price for the company in a research note on Friday, October 22nd. Morgan Stanley cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and set a $187.00 price objective for the company. in a research note on Tuesday, September 7th. Wells Fargo & Company restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, October 7th. Raymond James reduced their price objective on shares of Johnson & Johnson from $183.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, October 20th. Finally, SVB Leerink restated a “buy” rating on shares of Johnson & Johnson in a research note on Thursday, July 29th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $187.78.

Shares of JNJ stock opened at $160.69 on Wednesday. Johnson & Johnson has a 1 year low of $142.86 and a 1 year high of $179.92. The firm’s fifty day simple moving average is $162.74 and its 200 day simple moving average is $167.40. The firm has a market capitalization of $423.03 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 2.38 and a beta of 0.71. The company has a current ratio of 1.34, a quick ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Monday, October 18th. The company reported $2.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.35 by $0.25. Johnson & Johnson had a net margin of 19.55% and a return on equity of 37.90%. The business had revenue of $23.34 billion for the quarter, compared to analyst estimates of $23.72 billion. During the same quarter in the previous year, the firm posted $2.20 earnings per share. Johnson & Johnson’s revenue was up 10.7% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 9.78 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 7th. Investors of record on Tuesday, November 23rd will be given a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a yield of 2.64%. The ex-dividend date is Monday, November 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 63.38%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More: The four types of profit margin

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.